Over the last decade we have seen great strides taking place in the field of multiple myeloma as the disease has moved from an acute to a more chronic one with the advent of proteasome inhibitors and IMiDs. We’re still not curing many people, however.
The good news is there is now a raft of completely different agents with varying novel targets and modalities emerging at a rapid pace in early to near-term clinical development.
This raises some important strategic questions to think about for the future way beyond which ones look most promising because the bigger question is how will new regimens evolve to challenge the standard of care in each line of treatment?
CAR-T cell therapies are certainly in the mix here, but where will they be optimally used in the future, how do we go about figuring out which people should receive which particular option?
The issues at stake are much more complex than simply asking which BCMA directed therapy is going to be the ‘winner’ because myeloma doesn’t work like this given the preponderence of doublet and triplet regimens.
A better way of exploring new opportunities will be to consider who has what synergies with whom and how might they fit together in a more cogent and coherent fashion.
In order to explore the evolving multiple myeloma landscape, we decided to take a step back and explore the new options from a more strategic perspective. To accomplish this, we interviewed two companies who are active in this niche as well as some specialist thought leaders. It’s a highly relevant time to consider the issues given the broad discussions likely to emerge at JPM21 this week.
We kick off the latest mini-series with a look at the BMS pipeline opportunities in myeloma, who will be followed by J&J tomorrow, and finally discussion with a global expert on Wednesday – so without much ado, let’s roll!